OAB and Incontinence

“Along those lines, we've taken away the traditional step therapy that has dictated overactive bladder care for quite some time,” says Ariana L. Smith, MD, FPMRS.

Urinary symptoms were not significantly improved from local estrogen use in most studies, though an improvement in vaginal symptoms was observed.

The Prescription Drug User Fee Act target action date is set for quarter 3 of this year.

Following the positive recommendation, the European Commission will now review the application for vibegron for potential approval in the OAB setting in all EU member states, as well as in Iceland, Liechtenstein, and Norway.

“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.

Findings from the study showed a clinical response rate of 76.4% and 78.4% at 6- and 12-months following activation of the device among patients in the intent-to-treat population.

"There are plenty of articles written about stress-induced urgency. I, at the time, only found 1 article written in the gynecologic literature about what they called stand-up urgency," according to Colin Goudelocke, MD.

Colin Goudelocke, MD, offers insight on 2 abstracts from the 2024 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Winter Meeting.

"Even the possibility of something really big and revolutionary can still be exciting even if we're in the early stages," says Colin Goudelocke, MD.

Colin Goudelocke, MD, describes an abstract presented at the 2024 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Winter Meeting.

“I think 1 size doesn't fit all. We can't make a blanket statement that 1 of those types of therapy is better for all patients than another,” says Suzette E. Sutherland, MD, MS, FPMRS.

In the intervention group, the HRQOL score changed by 23.9 points between baseline and week 13, from 18.4 to 29.5.

“I think the long and short of it is we know tibial nerve stimulation works, we're just trying to identify what's the best way by which we can deliver it conveniently and cost effectively to the patient,” says Suzette E. Sutherland, MD, MS, FPMRS.

Tepidimonas was notably associated with more severe urinary incontinence episodes, suggesting a potential marker for identifying individuals at risk for more severe symptoms.

According to Axonics, commercial sales of the R20 system in Europe are expected to begin in mid-April.

“Currently, in the area of tibial nerve stimulation, there are only 2 FDA approved options,” says Suzette E. Sutherland, MD, MS, FPMRS.

"We're very much looking forward to being able to clinically implement these algorithms, both on the OAB side and the antibiotic resistance side," says Glenn T. Werneburg, MD, PhD.

The therapy, known as Autologous Muscle Derived Cells for Urinary Sphincter Repair (iltamiocel), involves a medical procedure in which a participant’s own muscle cells are collected, processed, and then injected into the tissues of the urinary passage.

The odds of SUI recurrence following MUS were 17% to 24% among patients with childbirth vs 15% to 22% among patients without childbirth

"We're really enthusiastic on the overactive bladder end and on the antibiotic resistance end, but much more broadly, [AI is] set up to help us counsel our patients better and help us to improve outcomes for our patients as well," says Glenn T. Werneburg, MD, PhD.

Artus is an artificial urinary sphincter for the treatment of patients with moderate to severe urinary incontinence.

"Our outcomes showed 71% of patients achieved dry or near dry results in 6 to 12 weeks," says Nissrine Nakib, MD.

"What we found was that we were able to identify patients who responded vs didn't respond to the treatment with a high degree of accuracy," says Glenn T. Werneburg, MD, PhD.

"I would say that the biggest take-home is that many of our patients are using social media for their health care information, and this may influence their preferences [and] their decision-making," says Alexandra Tabakin, MD.

In this episode, Dr. Kennelly, alongside Dr. Eilber and Dr. Benson, explores the advancements of transcutaneous and posterior tibial nerve stimulation (TTNS and PTNS) and sacral neuromodulation (SNM). The episode sheds light on how these therapies fit into current medical practices, their effectiveness, and the convenience they offer to patients. The specialists consider patient preferences and compliance challenges in choosing the right therapy. The episode provides a comprehensive understanding of how these therapies fit into patient-centric management plans, offering valuable insights for both patients and healthcare professionals.

In this insightful episode, Dr. Kennelly, along with Dr. Eilber and Dr. Benson, discuss the transition from pharmacologic treatments to third-line therapies for overactive bladder, focusing on the mechanism of action of various neuromodulation methods and benefits they offer to patients seeking sustainable solutions for OAB management.

The post-market RESTORE trial plans to enroll 150 patients with urge urinary incontinence across 20 clinical trial sites in the US.

"Probably the most surprising finding was actually that there were several videos created by health care professionals that contain misinformation," says Alexandra Tabakin, MD.

Interim data from the study showed that at 6 months following implantation, 80% (4 of 5) of evaluable women with mixed UI experienced a complete resolution of incontinence episodes.

Overall, the patient met the study’s primary outcome measures of successful device activation and the rate of explants and revisions at 6 months.